



Synthesis of novel steroidal 16-spiroisoxazolines by 1,3-dipolar
cycloaddition, and an evaluation of their antiproliferative
activities in vitro
Éva Frank · Dóra Kovács · Gyula Schneider ·
János Wölfling · Tibor Bartók · István Zupkó
Received: 20 November 2013 / Accepted: 7 March 2014
© Springer International Publishing Switzerland 2014
Abstract Efficient synthesis of novel 16-spiroisoxazolines
in the androst-5-ene series was carried out by 1,3-dipolar
cycloadditions of different aryl nitrile oxides to 3β-acetoxy-
16-methylene-androst-5-en-17-one. During the intermolec-
ular ring closures, the attack of the O terminus of the nitrile
oxide dipole from the α side on C-16 predominated for steric
reasons permitting the reactions to occur in a regio- and
stereoselective manner. The minor isomers in which the
angular methyl group on C-13 and the O atom of the isoxazo-
line heteroring were in the β, β-cis orientation were obtained
in a yield of only ∼10 %. Moreover, the conversions were
influenced to a certain extent by the substituents on the aro-
matic moiety of the 1,3-dipoles. The stereostructures of the
related diastereomers were confirmed by 2D NMR meth-
ods. Deacetylation of the primarily formed main products
resulted in the corresponding 3β-OH analogs, which were
further reduced to furnish 3β, 17β-diols. All of the syn-
thetized compounds were subjected to in vitro pharmaco-
logical studies in order to investigate their antiproliferative
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Introduction
Steroids, an important class of naturally occurring regulatory
molecules, are well known for their wide range of biologi-
cal activities and have gained extensive application in the
treatment of different diseases and in the improvement of
physical and growth performance. Chemical modifications
of the steroid nucleus, either by the introduction of hetero-
cyclic moieties or by the replacement of one or more car-
bon atoms by a heteroatom, thereby giving rise to marked
changes in the original bioactivity, have received consider-
able attention in recent years [1–3]. Considerable synthetic
efforts have been devoted to the search for more active com-
pounds untinged by unwanted or toxic side effects and to the
recognition of the stereostructural features required for spe-
cific receptor binding and therefore selective pharmacolog-
ical action. Consequently, both structure-based drug design
and a more random search for effective derivatives appear to
be fruitful routes in the quest for novel steroid-based medici-
nal agents. The formation of heterocyclic building blocks on
the sterane core may alter both the pharmacokinetic and the
pharmacodynamic properties of the parent compound, lead-
ing to hydrolysis-resistant derivatives with longer half-lives
and/or to a better fit to the corresponding target through addi-
tional interactions made possible by the presence of a hetero
ring. Moreover, the hydrophobic steroid scaffold can facili-
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tate the transportation of the introduced heterocycle through
biological membranes.
Among the members of the large steroid family, spiros-
teroids represent an important class of compounds that are
relatively widely found in nature, such as spirostanes and
spirosolanes, which include a spiroacetal or spiroaminoac-
etal moiety and display significant biological effects. The gly-
coalkaloids solasonine and tomatine, extracted from different
plant species, have demonstrated to exert strong antiprolif-
erative effects on various human cancer cell lines of diverse
origins [4,5], while the synthetic spiro-type hybrid of estrone
and talaromycin B has also been reported to exhibit cyto-
toxic activity [6,7]. In general, the spiro functionality, in
which two rings are connected through merely one carbon
atom, is a recurring structural motif in a number of natural
products with noteworthy biological activities [8]. For exam-
ple, coerulescine, horfiline, and elacomine exhibit antitumor
effects, whereas rynchophylline and corynoxeine are used in
traditional Chinese medicine for the treatment of neurologi-
cal and cardiovascular diseases [9,10].
The most investigated semi-synthetic spirosteroids are
those containing a spiro heteroring at C-17, but much less
has been published regarding the synthesis of C-16 spirohete-
rocyclic compounds [11]. Modifications involving the extant
17-keto functional group or the nearby position of the steroid
core with the introduction of a bulky heterocyclic moiety
can alter the primary stereostructure of the molecule, which
may lead to a change in the substrate-receptor interaction
and also greatly affect the biological properties. For this pur-
pose, a number of different heterocyclic systems have been
incorporated into the sterane skeleton in a spiro-connected
manner, particulary, oxazolidinones [12], pyrazolines [13],
pyrrolidines [14], dioxaphosphorinanes [15,16], oxazaphos-
pholes [17], and oxathiaphospholanes [18]. The chemistry of
steroidal spiroisoxazolines, however, has not been well inves-
tigated, although several 3- and 17-spiro derivatives have
been synthetized to date from the corresponding methylene
derivatives [19].
The established role of 2-isoxazolines as valuable inter-
mediates in organic synthesis is attributed to their capac-
ity to mask other functionalities within a stable form that
allows further substitution of the ring [20]. α,β-Unsaturated
ketones [21], β-hydroxycarbonyl compounds [22], and 1,3-
aminoalcohols [23] are the most important structural units
available from 2-isoxazolines by reductive cleavage of the
hetero ring. Although the isoxazoline building block appears
to be a rare functionality both in secondary metabolites found
in nature [20,24] and among marketed pharmaceutical agents
[25], several synthetic derivatives have been reported to
exhibit valuable biological activities [25,26]. Several meth-
ods have been devised to construct such bio-important com-
pounds, where the 1,3-dipolar cycloaddition of nitrile oxides
to an unsaturated substrate has been widely investigated [19].
Nitrile oxides are generally obtained in situ from their rela-
tively stable hydroximidoyl chloride precursors by dehydro-
halogenation with a base [27]. In the absence, and even in the
presence of the dipolarophile, nitrile oxides often rearrange to
form an isocyanate at higher temperature or tend to dimerize
to produce furoxan at room temperature, depending on their
structure, and these side reactions can reduce the yields of
the desired cycloadducts [28]. The Huisgen-type concerted
reaction often leads to a regioisomeric isoxazoline mixture
and needs elevated temperature and/or a prolonged reaction
time for sufficient conversion.
As a continuation of our work for the construction of het-
erocyclic steroids possessing cell-growth inhibitory effect
[29–32], we decided to prepare novel 16-spiroisoxazolinyl
androst-5-ene derivatives from an α,β-unsaturated steroidal
17-ketone via 1,3-dipolar cycloaddition. Our goal was to
investigate the regio- and stereoselectivity of the process and
the influence of steric and electronic factors on the ring-
closure reactions. Determination of the stereostructures of
the spiro compounds was also an aim of the present study.
Moreover, all the synthetized derivatives were screened in
vitro for their activities against a panel of three human adher-
ent cancer cell lines (HeLa, MCF7, and A431).
Results and discussion
Chemistry
For the transformations, the starting material was 3β-
acetoxy-16-methyleneandrost-5-en-17-one (2) [33], which
is readily available from the 16-hydroxymethylene precur-
sor 1 in the presence of an excess of formaldehyde and
potassium carbonate via a formal mixed Cannizzaro reaction
[34] and subsequent acetylation (Scheme 1). The presence
of the exo-methylene group suggested the higher reactivity
of the dipolarophile as compared to an endo-located double
bond, and improved regioselectivity was expected in view
of the monosubstituted character of the alkene moiety [27].
Moreover, conjugation with a C=O bond has been demon-
strated to have a strong driving effect on the reactivity of
such alkenes [35]. Aromatic hydroximidoyl chlorides (5a–
e), as relatively stable precursors of nitrile oxide 1,3-dipoles
(6a–e) [36], were synthetized in a two-step process by the
condensation of benzaldehyde (3a) or its p-substituted deriv-
atives (3b–e) with hydroxylamine hydrochloride in alkaline
medium and subsequent chlorination of the aldoxime 4a–e
with N -chlorosuccinimide (NCS) [37]. Nitrile oxides (6–e)
can be generated in situ from 5a–e by dehydrochlorination
with a base.
Preliminary ring-closure reactions on 2 with benzoni-
trile oxide 6a were first carried out to find the opti-
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Scheme 1 Regio- and stereoselective formation of steroidal 16-spiroisoxazolines
ketosteroid (2) and N -hydroxybenzenecarboximidoyl chlo-
ride (5a) were dissolved in toluene and 3 equivalents of N ,N -
diisopropylethylamine (DIPEA) were added. Since unhin-
dered 1,3-dipoles easily tend to dimerize to furoxanes, which
can reduce their quantity available for cycloaddition [38],
DIPEA was finally added to the solutions in order to avoid
the formation of these unwanted by-products. After stirring
of the mixtures for 2 h at room temperature, complete con-
version was indicated by TLC, and two products (7a and 8a)
were obtained, in yields of 75 and 10 %, respectively, after
chromatographic purification. Although the rate of the trans-
formation could be enhanced by refluxing the solution, and
the reaction was then completed within 1 h, the application
of milder conditions proved to be more favorable for further
experiments in order to avoid the rearrangement of other
dipoles to isocyanates at the elevated temperature. Similar
intermolecular ring closures of 2 with different benzonitrile
oxides (6b–e), obtained from the appropriate aryl aldehydes
(3b–e) by the general protocol, were then carried out lead-
ing to novel 16-spiroisoxazolines (7b–e and 8b–d) in good
yields (Scheme 1). The formation of the possible E and Z
isomers of both the aldoximes (4a–e) and their chlorinated
analogs (5a–e) was detected by TLC; however, the unpu-
rified hydroximidoyl chlorides (5a–e) were applied for the
subsequent cycloaddition reactions.
In principle, the construction of four isoxazolines (7–10)
can be conceived in the ring-closure reactions of 2 with aro-
matic nitrile oxides (6a–e), as depicted in Scheme 1. The
orientation of the 1,3-dipole relative to the double bond of
the dipolarophile can be of two kinds: the negatively charged
O terminus may interact with either the α-or the β-carbon of
the 16-methylene group of 2, and the attack can occur from
above (β side) or from underneath (α side) the general plane
of the sterane molecule. Two regioisomeric pairs (7, 8 and 9,
10), each involving two diastereomers, may therefore exist
as concerns the newly formed stereogenic center on C-16,
though only 7 and 8 (at least in most cases) were effectively
obtained during the cycloadditions. The formation of regioi-
123
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Table 1 Cycloaddition products
of 2 with different aromatic
nitrile oxides (6a–e)
a Yields (%) after purification






C Ar Productsa Overall yields (%)
1 6a Ph 7a (75) + 8a (10) 85
2 6b p-CH3-C6H4 7b (82) + 8b (9) 91
3 6c p-OMe-C6H4 7c (89) + 8c (6) 95
4 6d p-Cl-C6H4 7d (72) + 8d (8) 80
5 6e p-NO2-C6H4 7e (71) 71
somers (9 and 10) in which the O terminus is attached to
the β-carbon of the dipolarophile is considered to be ham-
pered by steric repulsions between the bulky aromatic ring
of the nitrile oxide and the steroid portion. The attack of the
anionic pole of the nitrile oxide from the β side is also unfa-
vorable due to the C-18 angular methyl group with the same
spatial orientation, although it does occur to a certain extent,
leading to 8 as a minor by-product. With regard to the pre-
sumed transition states (I–IV), the most facilitated isomer is
undoubtedly 7, in which the C-O bond of the heteroring is
located in the α position opposite the methyl group on C-13.
Consequently, both the regio- and the stereoselectivity of the
process are influenced by steric factors, in good agreement
with earlier observations that the electronic character of the
dipolarophile has only a minor effect on such reactions [39].
The overall yields of the epimeric products were affected
by the electronic character of the substituents on the aryl moi-
ety of the nitrile oxide 6b–e (Table 1). The electron-donating
CH3 and OMe groups in 6b and 6c (Table 1, entries 2 and 3)
facilitated the cycloaddition to 2 due to the lower propensity
of these dipoles to dimerize to furoxanes, while the presence
of the electron-withdrawing Cl and NO2 substituents on the
aromatic ring in 6d and 6e decreased the yields of the corre-
sponding cycloadducts (7d and 8d, or 7e) (entries 4 and 5).
The lowest conversion was found to occur for the reaction
of 2 with p-nitrobenzonitrile oxide 6e, which resulted in a
single diastereomer (7e) in a yield of 71 %.
The 13C NMR spectra recorded for 7a–e and 8a–d con-
firmed the regioselectivity of the process, as the quaternary
carbon signal of C-16 appeared at around 89 ppm, revealing
the presence of an O atom adjacent to this carbon. In the
other regioisomeric pairs (9 and 10), C-16 is next to C-5′
of the isoxazolidine ring and its upfield shift would there-
fore be predicted. The stereostructures of the related epimers
were established with the aid of homonuclear 2D NMR
(COSY and NOESY) and heteronuclear 2D NMR (HSQC
and HMBC) measurements. The two diastereotopic protons
of the C-4′ methylene group appear as two doublets at 3.25
and 3.63 ppm for 7b (2 JH,C,H = −16.5 Hz), and at 3.13
and 3.66 ppm for 8b (2 JH,C,H = −16.4 Hz), (Schemes 2
and 3). The NOESY correlations revealed that the C-16 con-
figuration is S in 7b as both signals of the 4′-protons showed
cross-peaks with the C-18 methyl protons, while one of the
doublets correlated with 15β-H (Scheme 2). The NOESY
experiment on cycloadduct 8b, however, supported the spa-
tial vicinity of 15α-H with one of the 4’-protons, showing a
cross-peak between their signals, confirming the R configu-
ration of C-16 in this case (Scheme 3).
For the enlargement of the compound library suitable for
pharmacological studies and in the hope of finding structure-
activity relationships, further derivatives of the main prod-
ucts (7a–e) were synthetized by simple deacetylations to fur-
nish the corresponding 3β-hydroxy analogs (11a–e). Further-
more, 3β,17β-diols (12a–e) were obtained by stereoselective
reduction of 11a–e (Scheme 4).
Pharmacology
Since a number of compounds of spiroisoxazoline type have
been reported to exert noteworthy antiproliferative activities
[40–42] and some steroidal derivatives containing similar
heterocyclic moieties have also been demonstrated to inhibit
cell proliferation [26,29,32], the newly synthetized isoxa-
zolines (7a–e, 8a–d, 11a–e, 12a–e) were subjected to in
vitro pharmacological studies of their cytotoxic effects on
three malignant human adherent cell lines, HeLa, MCF7,
and A431 (Table 2). Their antiproliferative activities were
determined by a microplate-based MTT colorimetric assay
[43], in comparison with cisplatin as reference agent. The
cell-proliferation inhibitory potencies, expressed as growth
inhibition and/or IC50 values, revealed that several of the
investigated compounds exhibited marked effects on cell pro-
liferation, especially at 30 μM.
As concerns the structure-activity relationships, the con-
figuration at C-16 of the newly synthetized molecules seems
to be the structural feature that mainly determines the antipro-
liferative properties, since 7a–d proved to be more potent
than their epimeric counterparts 8a–d. Substitution of the
aromatic ring on the isoxazoline moiety tended to increase
the antiproliferative capacity in 7b–d, while the p-nitro group
on the phenyl ring in 7e did not have a great impact on the
overall efficacy as compared with 7a. Although the keto func-
tion at position 17 of the sterane skeleton is generally favor-
able, this part of the molecule and also the nature of the
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Scheme 2 Partial NOESY
spectrum and 3D representation











substituent OAc or OH at C-3 did not have a crucial effect
on the overall antiproliferative activities. The IC50 values of
the two most potent agents, 7d and 11d, both containing a
p-chloro-phenyl-substituted isoxazoline building block with
an S configuration on C-16, were lower than or comparable
to those of the reference agent cisplatin.
Conclusions
In summary, novel types of spiroisoxazolines in the 5
androstene series were prepared from a 16-methylene-17-
ketosteroid with different aromatic nitrile oxides via inter-
molecular 1,3-dipolar cycloaddition. The ring-closure reac-
tions occurred under mild reaction conditions to afford the
heterocyclic products regioselectively and stereoselectively
in good to excellent yields. The conversions were observed
to increase by the presence of electron-donating groups on
the aromatic ring of the nitrile oxide in consequence of the
lower tendency of these dipoles to undergo dimerization. The
library of compounds was expanded by further deacetylation
reactions and subsequent reductions. The cytotoxic efficacy
of all compounds was investigated in vitro on three cancer
cell lines, and several of the structurally related derivatives
were found to have a marked effect on cell division. The phar-
macological activities depended mainly on the stereochem-
istry and functionalization of the incorporated heterocycle
rather than on the nature of the substituents on C-3 and/or C-
17 of the sterane core. Although only two derivatives of the
currently tested agents proved to be specifically potent, the
results indicate that steroidal spiroisoxazolines may deserve
further attention not only from a synthetic but also from a
pharmacological point of view.
Experimental
Melting points (mp) were determined on a SMS Optimelt dig-
ital apparatus. Elemental analysis data were obtained with a
Perkin Elmer CHN analyzer model 2400. NMR spectra were
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Scheme 3 Partial NOESY
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Scheme 4 Synthesis of 3β-hydroxy- and 3β,17β-dihydroxy-16-spiroisoxazolines
recorded at room temperature on a Bruker DRX 500 instru-
ment. Chemical shifts are reported in ppm (δ scale) and cou-
pling constants (J ) in Hz. For the determination of multiplic-
ities, the J -MOD pulse sequence was used. Automated flow
injection analyses were performed by using an HPLC/MSD
system. The system comprised an Agilent 1100 micro vac-
uum degasser, a quaternary pump, a micro-well plate autoin-
jector, and a 1946A MSD equipped with an electrospray ion
source (ESI) operated in positive ionization mode. The ESI
parameters were nebulizing gas N2, at 35 psi; drying gas
N2, at 350 ◦C and 12 L/min; capillary voltage (VCap) 3,000
V; and fragmentor voltage 70 V. The MSD was operated in
scan mode with the mass range m/z 60–620. Samples (0.2
μL) were injected with an automated needle wash directly
into the solvent flow (0.3 mL/min) of MeCN/H2O 70:30
(v/v) supplemented with 0.1 % formic acid. The system was
123
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Table 2 Cytotoxic activities of spiroisoxazolines in the androstene series
Compd Conc. (μM) HeLa ICa50 (μM) MCF7 IC50 (μM) A431 IC50 (μM)
Inhibition % (± SEM) Inhibition % (± SEM) Inhibition % (± SEM)
7a 10 59.7 (± 1.2) –b 53.5 (± 1.1) – 42.1 (± 1.1) –
30 81.5 (± 1.9) – 68.1 (± 1.0) – 48.0 (± 1.1) –
7b 10 82.5 (± 0.6) – 84.7 (± 0.5) – 65.9 (± 0.7) –
30 94.3 (± 1.3) – 94.0 (± 0.8) – 83.3 (± 0.5) –
7c 10 61.4 (± 1.2) – 66.0 (± 1.1) – 34.2 (± 2.2) –
30 86.7 (± 0.7) – 74.3 (± 0.6) – 58.2 (± 1.2) –
7d 10 97.7 (± 0.2) 7.46 92.0 (± 1.0) 8.07 98.1 (± 0.5) 3.42
30 98.5 (± 0.1) 95.6 (± 0.2) 98.1 (± 0.4)
7e 10 55.4 (± 1.2) – 56.1 (± 2.6) – 34.2 (± 1.3) –
30 55.8 (± 2.7) – 65.8 (± 1.4) – 38.3 (± 1.9) –
8a 10 <20c - <20 – <20 –
30 32.0 (± 1.1) – 64.7 (± 1.8) – <20 –
8b 10 <20 – 26.6 (± 2.9) – <20 –
30 59.8 (± 1.8) – 49.9 (± 1.3) – <20 –
8c 10 <20 – 20.8 (± 2.0) – <20 –
30 <20 – 31.8 (± 1.3) – <20 –
8d 10 33.5 (± 1.6) – 23.0 (± 0.7) – <20 –
30 72.4 (± 2.7) – 63.8 (± 1.4) – 30.5 (± 2.1) –
11a 10 <20 – 35.2 (± 1.2) – <20
30 96.8 (± 0.3) – 98.2 (± 0.3) – 95.8 (± 0.4)
11b 10 60.3 (± 0.6) - 51.5 (± 1.7) – 58.0 (± 1.2) –
30 82.5 (± 1.0) – 88.5 (± 0.7) – 76.1 (± 0.9) –
11c 10 42.7 (± 1.3) – 70.0 (± 1.4) – 30.6 (± 2.8)
30 82.3 (± 1.8) – 82.8 (± 1.4) – 41.4 (± 0.7)
11d 10 88.6 (± 2.7) 7.39 92.9 (± 0.3) 7.13 67.3 (± 2.9) 4.20
30 98.3 (± 0.2) 93.6 (± 1.1) 98.2 (± 0.1)
11e 10 <20 – <20 – <20 –
30 33.5 (± 1.3) – 30.1 (± 1.8) – 20.6 (± 2.6) –
12a 10 <20 – <20 – <20 –
30 97.6 (± 0.1) – 95.9 (± 1.4) – 95.6 (± 0.3) –
12b 10 36.4 (± 1.3) – <20 – <20 –
30 96.4 (± 0.4) - 98.6 (± 0.1) – 96.7 (± 0.5) –
12c 10 <20 – 26.4 (± 2.0) – <20 –
30 50.9 (± 0.7) – 74.1 (± 1.1) – 45.2 (± 2.4) –
12d 10 50.7 (± 0.7) – 32.4 (± 2.8) – 44.1 (± 0.8) –
30 57.7 (± 1.1) – 32.6 (± 1.4) – 46.7 (± 0.6) –
12e 10 58.8 (± 0.8) – 51.6 (± 1.6) – 61.4 (± 1.7) –
30 73.7 (± 1.9) – 73.8 (± 1.2) – 86.5 (± 0.8) –
CPd 10 42.6 (± 2.3) 12.43 53.0 (± 2.3) 9.63 88.6 (± 0.5) 2.84
30 99.9 (± 0.3) 86.9 (± 1.3) 90.2 (± 1.8)
a IC50 values were determined when the tested compound elicited at least 50 % growth inhibition at 10 μM against any of the cell lines used. The
presented values are from two independent determinations with five parallel wells; standard deviation <15 %
b Not determined
c Inhibition values <20 % are not presented
d Cisplatin (reference compound)
123
Mol Divers
controlled by Agilent’s LC/MSD Chemstation software. All
solvents were distilled immediately prior to use. Reagents
and materials were obtained from commercial suppliers and
were used without purification. The reactions were monitored
by TLC on Kieselgel-G (Merck Si 254 F) layers (0.25 mm
thick); solvent systems (ss): (A) EtOAc/CH2Cl2 (2:98 v/v),
(B) EtOAc/CH2Cl2 (10:90 v/v), (C) EtOAc/CH2Cl2 (25:75
v/v). The spots were developed by spraying with 5 % phos-
phomolybdic acid in 50 % aqueous phosphoric acid. The R f
values were determined for the spots observed by illumina-
tion at 254 and 365 nm. Flash chromatography: Merck silica
gel 60, 40–63 μm.
General procedure for the synthesis of 16-spiroisoxazolyl
derivatives (7 and 8) in the 5 androstene series
3β-Acetoxy-16-methyleneandrost-5-en-17-one (2) (343 mg,
1.00 mmol) and the appropriate aromatic imidoyl chloride
[36] (5a–e, 1.50 mmol) were dissolved in toluene (15 mL),
and DIPEA (0.52 mL, 3.00 mmol) was added dropwise to
the reaction mixture, which was subsequently stirred at room
temperature for 2 h. The solvent was then evaporated off in
vacuo and the resulting crude products were separated by
column chromatography.
Synthesis of 3β-acetoxy-3′-phenyl-spiro [androst-5-ene-
16,5′-2′-isoxazolin]-17-one epimers (7a and 8a)
According to Sect. 4.1, N -hydroxybenzenecarboximidoyl
chloride (5a, 233 mg) was used. After purification with
CH2Cl2 as eluent, 7a (346 mg, 75 %) and 8a (46 mg, 10
%) were obtained as white solids (sequence of elution: 8a >
7a).
7a: mp 245–248 ◦C, Rf = 0.38 (ss A); 1H NMR (CDCl3,
500 MHz): δH 0.97 (s, 3H, 18-H3), 1.06 (s, 3H, 19-H3), 1.14
(m, 2H), 1.48–1.75 (overlapping m, 8H), 1.86–1.96 (over-
lapping m, 3H), 2.03 (s, 3H, Ac-CH3), 2.04 (m, 1H), 2.35
(m, 3H), 3.27 (d, 1H, J = 16.6 Hz, one of 4′-H), 3.65 (d, 1H,
J= 16.6 Hz, the other 4′-H), 4.60 (m, 1H, 3-H), 5.40 (m, 1H,
6-H), 7.38 (m, 3H, 3′′-H, 4′′-H and 5′′-H), 7.63 (m, 2H, 2′′-H
and 6′′-H); 13C NMR (CDCl3, 125 MHz): δC 14.3(C-18),
19.3 (C-19), 20.2 (CH2), 21.4 (Ac-CH3), 27.6 (CH2), 30.7
(CH2), 31.0 (CH), 31.6 (CH2), 36.7 (C-10), 36.8 (CH2), 37.5
(CH2), 38.0 (CH2), 44.0 (CH2), 47.1 (C-13), 48.5 (CH), 49.9
(CH), 73.6 (C-3), 88.7 (C-16), 121.7 (C-6), 126.8 (2C, C-3′′
and C-5′′), 128.7 (2C, C-2′′ and C-6′′), 129.0 (C-1′′), 130.2
(C-4′′), 139.9 (C-5), 155.3 (C-3′′), 170.4 (Ac-CO), 216.2 (C-
17); ESI-MS 485 [M+Na]+; Anal. Calcd. for C29H35NO4 C
75.46; H 7.64. Found C 75.62; H 7.80.
8a: mp 187–190 ◦C, Rf = 0.44 (ss A); 1H NMR (CDCl3,
500 MHz): δH 1.05 (m, 1H), 1.07 (s, 3H, 19-H3), 1.11 (s,
3H, 18-H3), 1.15 (m, 2H), 1.34 (m, 1H), 1.52–1.66 (m, 3H),
1.70–1.80 (m, 2H), 1.88–1.98 (m, 3H), 2.03 (s, 3H, Ac-CH3),
2.04 (m, 1H), 2.08 (m, 1H), 2.24 (dd, 1H, J = 13.1 Hz, J
= 5.8 Hz), 2.35 (m, 2H), 3.14 (d, 1H, J= 16.4 Hz, one of
4′-H), 3.69 (d, 1H, J = 16.4 Hz, the other 4′-H), 4.61 (m, 1H,
3-H), 5.39 (m, 1H, 6-H), 7.39 (m, 3H, 3′′-H, 4′′-H and 5′′-
H), 7.64 (m, 2H, 2′′-H and 6′′-H); 13C-NMR (CDCl3, 125
MHz): δC 14.3(C-18), 19.3 (C-19), 20.1 (CH2), 21.4 (Ac-
CH3), 27.6 (CH2), 30.8 (CH2), 30.9 (CH), 31.9 (CH2), 36.8
(C-10), 36.9 (CH2), 38.0 (2C, 2 × CH2), 45.4 (CH2), 46.4
(CH), 46.8 (C-13), 50.2 (CH), 73.6 (C-3), 88.6 (C-16), 121.4
(C-6), 126.8 (2C, C-3′′ and C-5′′), 128.7 (2C, C-2′′ and C-
6′′), 129.0 (C-1′′), 130.2 (C-4′′), 140.0 (C-5), 155.0 (C-3′),
170.5 (Ac-CO), 215.4 (C-17); ESI-MS 485 [M+Na]+; Anal.
Calcd. for C29H35NO4 C 75.46; H 7.64. Found C 75.60; H
7.78.
Synthesis of 3β-acetoxy-3′-4′′-tolyl-spiro[androst-5-ene-
16,5′-2′-isoxazolin]-17-one epimers (7b and 8b)
According to Sect. 4.1, N -hydroxy-4-methylbenzenecar-
boximidoyl chloride (5b, 254 mg) was used. After purifi-
cation with EtOAc/CH2Cl2 = 2:98 as eluent, 7b (390 mg,
82 %) and 8b (43 mg, 9 %) were obtained as white solids
(sequence of elution: 8b > 7b).
7b: mp 240–242 ◦C, R f = 0.32 (ss A); 1H NMR (CDCl3,
500 MHz): δH 0.96 (s, 3H, 18-H3), 1.05 (s, 3H, 19-H3), 1.50
(m, 2H), 1.48–1.77 (overlapping m, 8H), 1.88 (m, 2H), 1.95
(m, 1H), 2.03 (s, 3H, Ac-CH3), 2.05 (m, 1H), 2.34 (m, 3H),
2.37 (s, 3H, 4′′-CH3), 3.25 (d, 1H, J = 16.5 Hz, one of 4′-H),
3.63 (d, 1H, J= 16.5 Hz, the other 4′-H), 4.61 (m, 1H, 3-H),
5.40 (m, 1H, 6-H), 7.19 (d, 2H, J = 8.0 Hz, 3′′-H and 5′′-H),
7.53 (d, 2H, J = 8.0 Hz, 2′′-H and 6′′-H); 13C NMR (CDCl3,
125 MHz): δC 14.3 (C-18), 19.3 (C-19), 20.2 (CH2), 21.4
(2C, 4′′-CH3 and Ac-CH3), 27.6 (CH2), 30.6 (CH2), 31.0
(CH), 31.6 (CH2), 36.7 (C-10), 36.8 (CH2), 37.6 (CH2), 38.0
(CH2), 44.2 (CH2), 47.1 (C-13), 48.5 (CH), 49.9 (CH), 73.6
(C-3), 88.5 (C-16), 121.7 (C-6), 126.2 (C-1′′), 126.8 (2C, C-
2′′ and C-6′′), 129.4 (2C, C-3′′ and C-5′′), 139.8 (C-4′′), 140.4
(C-5), 155.3 (C-3′), 170.4 (Ac-CO), 216.4 (C-17); ESI-MS
477 [M+H]+; Anal. Calcd. for C30H37NO4 C 75.76; H 7.84.
Found C 75.92; H 8.00.
8b: mp 193–195 ◦C, Rf = 0.51 (ss A); 1H NMR (CDCl3,
500 MHz): δH 1.05 (m, 1H), 1.06 (s, 3H, 19-H3), 1.11 (s,
3H, 18-H3), 1.15 (m, 2H), 1.34 (m, 1H), 1.51–1.66 (m, 3H),
1.70–1.79 (m, 2H), 1.87-1.99 (m, 3H), 2.02 (m, 1H), 2.03
(s, 3H, Ac-CH3), 2.08 (m, 1H), 2.23 (dd, 1H, J = 13.1 Hz,
J = 5.7 Hz), 2.35 (m, 2H), 2.37 (s, 3H, 4′′-CH3), 3.13 (d,
1H, J= 16.4 Hz, one of 4′-H), 3.66 (d, 1H, J = 16.4 Hz, the
other 4′-H), 4.61 (m, 1H, 3-H), 5.39 (m, 1H, 6-H), 7.19 (d,
2H, J = 8.0 Hz, 3′′-H and 5′′-H), 7.53 (d, 2H, J = 8.0 Hz,
2′′-H and 6′′-H); 13C NMR (CDCl3, 125 MHz): δC 130.0
(C-18), 19.3 (C-19), 20.1 (CH2), 21.4 (2C, 4′′-CH3 and Ac-
CH3), 27.6 (CH2), 30.8 (CH2), 30.9 (CH), 31.8 (CH2), 36.8
(C-10), 36.9 (CH2), 38.0 (2C, 2 × CH2), 45.6 (CH2), 46.4
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(CH), 46.8 (C-13), 50.2 (CH), 73.6 (C-3), 88.5 (C-16), 121.4
(C-6), 126.1 (C-1′′), 126.8 (2C, C-2′′ and C-6′′), 129.4 (2C,
C-3′′ and C-5′′), 140.0 (C-4′′), 140.5 (C-5), 154.9 (C-3′),
170.5 (Ac-CO), 215.5 (C-17); ESI-MS 477 [M+H]+; Anal.
Calcd. for C30H37NO4 C 75.76; H 7.84. Found C 75.62; H
7.94.
Synthesis of 3β-acetoxy-3′-4′′-methoxyphenyl-spiro
[androst-5-ene-16,5′-2′-isoxazolin]-17-one epimers (7c and
8c)
According to Sect. 4.1, N -hydroxy-4-methoxybenzenecar-
boximidoyl chloride (5c, 279 mg) was used. After purifica-
tion with CH2Cl2 as eluent, 7c (438 mg, 89 %) and 8c (29
mg, 6 %) were obtained as white solids (sequence of elution:
7c > 8c).
7c: mp 248–250 ◦C, Rf = 0.26 (ss A); 1H NMR (CDCl3,
500 MHz): δH 0.97 (s, 3H, 18-H3), 1.05 (s, 3H, 19-H3), 1.15
(m, 2H), 1.47–1.76 (overlapping m, 8H), 1.88 (m, 2H), 1.94
(m, 1H), 2.03 (s, 3H, Ac-CH3), 2.04 (m, 1H), 2.35 (m, 3H),
3.24 (d, 1H, J = 16.5 Hz, one of 4′-H), 3.62 (d, 1H, J= 16.5
Hz, the other 4′-H), 3.83 (s, 3H, 4′′-OMe), 4.61 (m, 1H, 3-
H), 5.40 (m, 1H, 6-H), 6.90 (d, 2H, J = 8.6 Hz, 3′′-H and
5′′-H), 7.58 (d, 2H, J = 8.6 Hz, 2′′-H and 6′′-H); 13C NMR
(CDCl3, 125 MHz): δC14.3 (C-18), 19.3 (C-19), 20.1(CH2),
21.4 (Ac-CH3), 27.6 (CH2), 30.6 (CH2), 31.0 (CH), 31.6
(CH2), 36.7 (C-10), 36.8 (CH2), 37.5 (CH2), 38.0 (CH2),
44.2 (CH2), 47.1 (C-13), 48.5 (CH), 49.9 (CH), 55.3 (4′′-
OMe), 73.6 (C-3), 88.4 (C-16), 114.1 (2C, C-3′′ and C-5′′),
121.5 (C-1′′), 121.7 (C-6), 128.4 (2C, C-2′′ and C-6′′), 139.8
(C-5), 154.9 (C-3′), 161.1 (C-4′′), 170.4 (Ac-CO), 216.4 (C-
17); ESI-MS 515 [M+Na]+; Anal. Calcd. for C30H37NO5 C
73.29; H 7.59. Found C 73.42; H 7.74.
8c: mp 197–200 ◦C, Rf = 0.34 (ss A); 1H NMR (CDCl3,
500 MHz): δH 0.88 (m, 1H), 1.07 (m, 3H, 18-H3), 1.10 (s,
3H, 19-H3), 1.15 (m, 2H), 1.34 (m, 1H), 1.52–1.65 (m, 3H),
1.70–1.81 (m, 2H), 1.88–1.99 (m, 3H), 2.03 (s, 3H, Ac-CH3),
2.04 (m, 1H), 2.09 (m, 1H), 2.23 (dd, 1H, J = 13.0 Hz, J
= 5.6 Hz), 2.34 (m, 2H), 3.11 (d, 1H, J= 16.3 Hz, one of
4′-H), 3.65 (d, 1H, J = 16.3 Hz, the other 4′-H), 3.83 (s, 3H,
4′′-OMe), 4.61 (m, 1H, 3-H), 5.39 (m, 1H, 6-H), 6.90 (d,
2H, J = 8.4 Hz, 3′′-H and 5′′-H), 7.58 (d, 2H, J = 8.4 Hz,
2′′-H and 6′′-H); 13C NMR (CDCl3, 125 MHz): δC13.0 (C-
18), 19.3 (C-19), 20.1 (CH2), 21.4 (Ac-CH3), 27.6 (CH2),
29.7 (CH2), 30.8 (CH2), 30.9 (CH), 31.9 (CH2), 36.8 (C-
10), 36.9 (CH2), 38.0 (CH2), 45.7 (CH2), 46.5 (CH), 46.8
(C-13), 50.2 (CH), 55.3 (4′′-OMe), 73.6 (C-3), 88.4 (C-16),
114.1 (2C, C-3′′ and C-5′′), 121.4 (C-6), 121.5 (C-1′′), 128.4
(2C, C-2′′ and C-6′′), 140.0 (C-5), 154.5 (C-3′), 161.1 (C-4′′),
170.5 (Ac-CO), 215.6 (C-17); ESI-MS 515 [M+Na]+; Anal.
Calcd. for C30H37NO5 C 73.29; H 7.59. Found C 73.39;
H 7.78.
Synthesis of 3β-acetoxy-3′-4′′-chlorophenyl-spiro[androst-
5-ene-16,5′-2′-isoxazolin]-17-one epimers (7d and 8d)
According to Sect. 4.1, N -hydroxy-4-chlorobenzenecar-
boximidoyl chloride (5d, 285 mg) was used. After purifi-
cation with CH2Cl2 as eluent, 7d (357 mg, 72 %) and 8d (40
mg, 8 %) were obtained as white solids (sequence of elution:
8d > 7d).
7d: mp 226–228 ◦C, Rf = 0.40 (ss A); 1H NMR (CDCl3,
500 MHz): δH 0.96 (s, 3H, 18-H3), 1.05 (s, 3H, 19-H3), 1.14
(m, 2H), 1.47–1.76 (overlapping m, 8H), 1.88 (m, 2H), 1.95
(m, 1H), 2.03 (s, 3H, Ac-CH3), 2.04 (m, 1H), 2.36 (m, 3H),
3.24 (d, 1H, J = 16.6 Hz, one of 4′-H), 3.62 (d, 1H, J= 16.6
Hz, the other 4′-H), 4.61 (m, 1H, 3-H), 5.41 (m, 1H, 6-H),
7.37 (d, 2H, J = 8.6 Hz, 3′′-H and 5′′-H), 7.58 (d, 2H, J
= 8.6 Hz, 2′′-H and 6′′-H); 13C NMR (CDCl3, 125 MHz):
δC 14.3 (C-18), 19.3 (C-19), 20.1 (CH2), 21.4 (Ac-CH3),
27.6 (CH2), 30.6 (CH2), 31.0 (CH), 31.6 (CH2), 36.7 (C-
10), 36.8 (CH2), 37.5 (CH2), 38.0 (CH2), 43.7 (CH2), 47.1
(C-13), 48.5 (CH), 49.9 (CH), 73.6 (C-3), 88.9 (C-16), 121.6
(C-6), 127.5 (C-1′′), 128.0 (2C, C-3′′ and C-5′′), 129.0 (2C,
C-2′′ and C-6′′), 136.2 (C-4′′), 139.9 (C-5), 154.4 (C-3′),
170.4 (Ac-CO), 216.0 (C-17); ESI-MS 519 [M+Na]+; Anal.
Calcd. for C29H34ClNO4 C 70.22; H 6.91. Found C 70.37;
H 7.08.
8d: Decomposed above 190 ◦C, Rf = 0.54 (ss A); 1H NMR
(CDCl3, 500 MHz): δH 1.06 (m, 1H), 1.06 (s, 3H, 19-H3),
1.10 (s, 3H, 18-H3), 1.14 (m, 2H), 1.33 (m, 1H), 1.52–1.65
(m, 3H), 1.70–1.79 (m, 2H), 1.87-1.97 (m, 3H), 2.03 (s, 3H,
Ac-CH3), 2.05 (m, 1H), 2.08 (m, 1H), 2.23 (dd, 1H, J = 12.9
Hz, J = 5.3 Hz), 2.34 (m, 2H), 3.10 (d, 1H, J= 16.4 Hz,
one of 4′-H), 3.64 (d, 1H, J = 16.4 Hz, the other 4′-H), 4.60
(m, 1H, 3-H), 5.39 (m, 1H, 6-H), 7.37 (d, 2H, J = 8.0 Hz,
3′′-H and 5′′-H), 7.57 (d, 2H, J = 8.0 Hz, 2′′-H and 6′′-H);
13C NMR (CDCl3, 125 MHz): δC13.0 (C-18), 19.3 (C-19),
20.1 (CH2), 21.4 (Ac-CH3), 27.6 (CH2), 30.8 (CH2), 30.9
(CH), 31.8 (CH2), 36.8 (C-10), 36.9 (CH2), 37.9 (CH2), 38.0
(CH2), 45.2 (CH2), 46.4 (CH), 46.8 (C-13), 50.2 (CH), 73.6
(C-3), 88.9 (C-16), 121.4 (C-6), 127.5 (C-1′′), 128.1 (2C, C-
3′′ and C-5′′), 129.0 (2C, C-2′′ and C-6′′), 136.2 (C-4′′), 140.0
(C-5), 154.1 (C-3′), 170.5 (Ac-CO), 215.2 (C-17); ESI-MS
519 [M+Na]+; Anal. Calcd. for C29H34ClNO4 C 70.22; H
6.91. Found C 70.05; H 7.05.
Synthesis of 3β-acetoxy-3′-4′′-nitrophenyl-
spiro[androst-5-ene-16,5′-2′-isoxazolin]-17-one (7e)
According to Sect. 4.1, N -hydroxy-4-nitrobenzenecar-
boximidoyl chloride (5e, 300 mg) was used. After purifi-
cation with EtOAc/CH2Cl2 = 1:99 as eluent, 7e (360 mg, 71
%) was obtained as a pale-yellow solid.
7e: mp 233–235 ◦C, Rf = 38 (ss A); 1H NMR (CDCl3, 500
MHz): δH 0.97 (s, 3H, 18-H3), 1.06 (s, 3H, 19-H3), 1.15 (m,
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2H), 1.48-1.79 (overlapping m, 8H), 1.88 (m, 2H), 1.96 (m,
1H), 2.03 (s, 3H, Ac-CH3), 2.04 (m, 1H), 2.35 (m, 3H), 3.30
(d, 1H, J = 16.6 Hz, one of 4′-H), 3.65 (d, 1H, J= 16.6 Hz,
the other 4′-H), 4.61 (m, 1H, 3-H), 5.40 (m, 1H, 6-H), 7.80 (d,
2H, J = 8.6 Hz, 2′′-H and 6′′-H), 8.25 (d, 2H, J = 8.6 Hz,
3′′-H and 5′′-H); 13C NMR (CDCl3, 125 MHz): δC14.4 (C-
18), 19.3 (C-19), 20.1 (CH2), 21.4 (Ac-CH3), 27.6 (CH2),
30.6 (CH2), 31.0 (CH), 31.6 (CH2), 36.7 (C-10), 36.8 (CH2),
37.4 (CH2), 38.0 (CH2), 43.1 (CH2), 47.1 (C-13), 48.6 (CH),
49.9 (CH), 73.6 (C-3), 89.7 (C-16), 121.5 (C-6), 124.0 (2C,
C-3′′ and C-5′′), 127.5 (2C, C-2′′ and C-6′′), 135.1 (C-
1′′), 140.0 (C-5), 148.5 (C-4′′), 153.8 (C-3′), 170.4 (Ac-
CO), 215.5 (C-17); ESI-MS 530 [M+Na]+; Anal. Calcd. for
C29H34N2O6 C 68.76; H 6.76. Found C 68.89; H 6.92.
General procedure for the deacetylation of
16-spiroisoxazolyl derivatives (7a–e)
Compound 7a–e (0.60 mmol) was dissolved in MeOH (10
mL), and KOH (50 mg, 0.89 mmol) was added. The solution
was stirred at room temperature for 8 h, then diluted with
water and neutralized with dilute HCl. The resulting precip-
itate was filtered, washed with water, and dried.
Synthesis of 3β-hydroxy-3′-phenyl-spiro[androst-5-ene-
16,5′S-2′-isoxazolin]-17-one (11a)
Substrate: 7a (277 mg). 11a was obtained as a white solid
(229 mg, 91 %), mp 223–226 ◦C, Rf = 0.37 (ss B); 1H NMR
(CDCl3, 500 MHz): δH 0.97 (s, 3H, 18-H3), 1.04 (s, 3H, 19-
H3), 1.11 (m, 2H), 1.52 (m, 3H), 1.65–1.76 (overlapping m,
5H), 1.86 (m, 2H), 1.95 (m, 1H), 2.05 (m, 1H), 2.24 (m, 1H),
2.32 (m, 1H), 2.39 (m, 1H), 3.28 (d, 1H, J = 16.6 Hz, one
of 4′-H), 3.54 (m, 1H, 3-H), 3.65 (d, 1H, J = 16.6 Hz, the
other 4′-H), 5.37 (m, 1H, 6-H), 7.40 (m, 3H, 3′′-H, 4′′-H and
5′′-H), 7.64 (m, 2H, 2′′-H and 6′′-H); 13C NMR (CDCl3, 125
MHz): δC14.3 (C-18), 19.4 (C-19), 20.2 (CH2), 30.7 CH2),
31.0 (CH), 31.5 (CH2), 31.6 (CH2), 36.6 (C-10), 37.0 (CH2),
37.5 (CH2), 42.1 (CH2), 44.0 (CH2), 47.1 (C-13), 48.6 (CH),
50.0 (CH), 71.5 (C-3), 88.7 (C-16), 120.7 (C-6), 126.8 (2C,
C-3′′ and C-5′′), 128.7 (2C, C-2′′ and C-6′′), 129.0 (C-1′′),
130.2 (C-4′′), 141.0 (C-5), 155.4 (C-3′), 216.3 (C-17); ESI-
MS 443 [M+Na]+; Anal. Calcd. for C27H33NO3 C 77.29; H
7.93. Found C 77.43; H 8.15.
Synthesis of 3β-hydroxy-3′-4′′-tolyl-spiro[androst-5-
ene-16,5′S-2′-isoxazolin]-17-one (11b)
Substrate: 7b (285 mg). 11b was obtained as a white solid
(239 mg, 92 %), mp 270–272 ◦C, Rf = 0.37 (ss B); 1H NMR
(CDCl3, 500 MHz): δH 0.96 (s, 3H, 18-H3), 1.04 (s, 3H,
19-H3), 1.10 (m, 2H), 1.51 (m, 3H), 1.65-1.77 (overlapping
m, 5H), 1.86 (m, 2H), 1.94 (m, 1H), 2.03 (m, 1H), 2.24 (m,
1H), 2.36 (m, 2H), 2.37 (s, 3H, 4′′-CH3), 3.26 (d, 1H, J
= 16.5 Hz, one of 4′-H), 3.54 (m, 1H, 3-H), 3.63 (d, 1H,
J = 16.5 Hz, the other 4′-H), 5.37 (m, 1H, 6-H), 7.19 (d,
2H, J = 8.0 Hz, 3′′-H and 5′′-H), 7.53 (d, 2H, J = 8.0 Hz,
2′′-H and 6′′-H); 13C NMR (CDCl3, 125 MHz): δC = 14.3
(C-18), 19.4 (C-19), 20.2 (CH2), 21.4 (4′′-CH3), 30.7 (CH2),
31.0 (CH), 31.5 (CH2), 31.6 (CH2), 36.6 (C-10), 37.1 (CH2),
37.6 (CH2), 42.1 (CH2), 44.2 (CH2), 47.1 (C-13), 48.6 (CH),
50.0 (CH), 71.5 (C-3), 88.5 (C-16), 120.8 (C-6), 126.1 (C-
1′′), 126.8 (2C, C-2′′ and C-6′′), 129.4 (2C, C-3′′ and C-5′′),
140.5 (C-4′′), 140.9 (C-5), 155.4 (C-3′), 216.4 (C-17); ESI-
MS 435 [M+H]+; Anal. Calcd. for C28H35NO3 C 77.56; H
8.14. Found C 77.42; H 8.20.
Synthesis of 3β-hydroxy-3′-4′′-methoxyphenyl-
spiro[androst-5-ene-16,5′S-2′-isoxazolin]-17-one (11c)
Substrate: 7c (295 mg). 11c was obtained as a white solid
(245 mg, 91 %), mp 254–255 ◦C, Rf = 0.29 (ss B); 1H NMR
(CDCl3, 500 MHz): δH 0.96 (s, 3H, 18-H3), 1.04 (s, 3H, 19-
H3), 1.10 (m, 2H), 1.52 (m, 3H), 1.65–1.72 (overlapping m,
5H), 1.86 (m, 2H), 1.94 (m, 1H), 2.03 (m, 1H), 2.24 (m, 1H),
2.32 (m, 1H), 2.38 (m, 1H), 3.25 (d, 1H, J = 16.5 Hz, one
of 4′-H), 3.54 (m, 1H, 3-H), 3.62 (d, 1H, J = 16.5 Hz, the
other 4′-H), 3.83 (s, 3H, 4′′-OMe), 5.37 (m, 1H, 6-H), 6.90
(d, 2H, J = 8.5 Hz, 3′′-H and 5′′-H), 7.58 (d, 2H, J = 8.5 Hz,
2′′-H and 6′′-H); 13C NMR (CDCl3, 125 MHz): δC 14.3 (C-
18), 19.4 (C-19), 20.2 (CH2), 30.7 (CH2), 31.0 (CH), 31.5
(CH2), 31.6 (CH2), 36.6 (C-10), 37.0 (CH2), 37.6 (CH2),
42.1 (CH2), 44.3 (CH2), 47.1 (C-13), 48.6 (CH), 50.0 (CH),
55.3 (4′′-OMe), 71.5 (C-3), 88.4 (C-16), 114.1 (2C, C-3′′ and
C-5′′), 120.8 (C-6), 121.5 (C-1′′), 128.4 (2C, C-2′′ and C-6′′),
140.9 (C-5), 155.0 (C-3′), 161.1 (C-4′′), 216.5 (C-17); ESI-
MS 473 [M+Na]+; Anal. Calcd. for C28H35NO4 C 74.80; H
7.85. Found C 74.96; H 8.02.
Synthesis of 3β-hydroxy-3′-4′′-chlorophenyl-
spiro [androst-5-ene-16,5′S-2′-isoxazolin]-17-one (11d)
Substrate: 7d (298 mg). 11d was obtained as a white solid
(259 mg, 95 %), mp 256–259 ◦C, Rf = 0.38 (ss B); 1H NMR
(CDCl3, 500 MHz): δH 0.95 (s, 3H, 18-H3), 1.04 (s, 3H,
19-H3), 1.12 (m, 2H), 1.47-1.78 (overlapping m, 8H), 1.87
(m, 2H), 1.96 (m, 1H), 2.05 (m, 1H), 2.24 (m, 1H), 2.34 (m,
1H), 2.41 (m, 1H), 3.25 (d, 1H, J = 16.6 Hz, one of 4′-H),
3.54 (m, 1H, 3-H), 3.61 (d, 1H, J= 16.6 Hz, the other 4′-H),
5.36 (m, 1H, 6-H), 7.36 (d, 2H, J = 8.6 Hz, 3′′-H and 5′′-H),
7.57 (d, 2H, J = 8.6 Hz, 2′′-H and 6′′-H); 13C-NMR (CDCl3,
125 MHz): δC = 14.3 (C-18), 19.4 (C-19), 20.2 (CH2), 30.6
(CH2), 31.0 (CH), 31.5 (CH2), 31.6 (CH2), 36.6 (C-10), 37.0
(CH2), 37.5 (CH2), 42.1 (CH2), 43.8 (CH2), 47.1 (C-13),
48.6 (CH), 50.0 (CH), 71.4 (C-3), 89.0 (C-16), 120.7 (C-6),
127.5 (C-1′′), 128.0 (2C, C-3′′ and C-5′′), 129.0 (2C, C-2′′
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and C-6′′), 136.2 (C-4′′), 141.0 (C-5), 154.5 (C-3′), 216.1 (C-
17); ESI-MS 477 [M+H]+; Anal. Calcd. for C27H32ClNO3
C 71.43; H 7.10. Found C 71.52; H 7.29.
Synthesis of 3β-hydroxy-3′-4′′-nitrophenyl-
spiro[androst-5-ene-16,5′S-2′-isoxazolin]-17-one(11e)
Substrate: 7e (304 mg). 11e was obtained as a yellow solid
(262 mg, 94 %), mp 265–268 ◦C, Rf = 0.37 (ss B); 1H NMR
(CDCl3, 500 MHz): δH 0.98 (s, 3H, 18-H3), 1.05 (s, 3H, 19-
H3), 1.12 (m, 2H), 1.48-1.79 (overlapping m, 8H), 1.87 (m,
2H), 1.97 (m, 1H), 2.05 (m, 1H), 2.24 (m, 1H), 2.33 (m, 1H),
2.42 (m, 1H), 3.30 (d, 1H, J = 16.6 Hz, one of 4′-H), 3.54
(m, 1H, 3-H), 3.66 (d, 1H, J= 16.6 Hz, the other 4′-H), 5.40
(m, 1H, 6-H), 7.81 (d, 2H, J = 8.7 Hz, 2′′-H és 6′′-H), 8.25
(d, 2H, J = 8.6 Hz, 3′′-H és 5′′-H); 13C NMR (CDCl3, 125
MHz): δC 14.0 (C-18), 19.0 (C-19), 19.8 (CH2), 30.3 (CH2),
30.6 (CH), 31.1 (CH2), 31.2 (CH2), 36.3 (C-10), 36.7 (CH2),
37.0 (CH2), 41.7 (CH2), 42.8 (CH2), 46.8 (C-13), 48.2 (CH),
49.6 (CH), 71.1 (C-3), 89.4 (C-16), 120.2 (C-6), 123.6 (2C,
C-3′′ and C-5′′), 127.2 (2C, C-2′′ and C-6′′), 134.7 (C-1′′),
140.6 (C-5), 148.1 (C-4′′), 153.5 (C-3′), 215.2 (C-17); ESI-
MS 488 [M+Na]+; Anal. Calcd. for C27H32N2O5 C 69.81;
H 6.94. Found C 69.96; H 7.08.
General procedure for the reduction of 16-spiroisoxazolyl
derivatives (11a–e)
Compound 11a–e (0.45 mmol) was dissolved in a mixture
of MeOH (10 mL) and THF (10 mL), and KBH4 (50 mg,
0.93 mmol) was added. The solution was stirred at room
temperature for 1 h, then diluted with water and neutral-
ized with dilute HCl. The resulting precipitate was filtered,
washed with water, and purified by flash chromatography
with EtOAc/CH2Cl2 = 20:80 as eluent.
Synthesis of 3β-hydroxy-3′-phenyl-spiro[androst-5-ene-
16,5′S-2′-isoxazolin]-17β-ol (12a)
Substrate: 11a (189 mg). 12a was obtained as a white solid
(186 mg, 98 %), mp 233–236 ◦C, Rf = 0.44 (ss C); 1H NMR
(DMSO-d6, 500 MHz): δH 0.67 (s, 3H, 18-H3), 0.95 (s, 3H,
19-H3), 0.99 (m, 2H), 1.18 (m, 2H), 1.32–1.42 (overlapping
m, 3H), 1.48–1.56 (overlapping m, 3H), 1.69 (m, 1H), 1.76
(m, 2H), 1.88 (m, 1H), 2.00 (m, 1H), 2.06-2.17 (overlapping
m, 2H), 3.00 (d, 1H, J = 17.1 Hz, one of 4′-H), 3.27 (m, 1H,
3-H), 3.62 (d, 1H, J = 4.9 Hz, 17-H), 3.78 (d, 1H, J = 17.1
Hz, the other 4′-H), 4.63 (d, 1H, J = 4.3 Hz, 3-OH), 5.26
(m, 1H, 6-H), 5.33 (d, 1H, J = 4.9 Hz, 17-OH), 7.42 (m,
3H, 3′′-H, 4′′-H and 5′′-H), 7.66 (m, 2H, 2′′-H and 6′′-H);
13C NMR (DMSO-d6, 125 MHz): δC 11.4 (C-18), 19.1 (C-
19), 20.0 (CH2), 30.8 (CH), 30.9 (CH2), 31.3 (CH2), 36.2
(CH2), 36.3 (C-10), 36.8 (CH2), 41.1 (CH2), 41.6 (C-13),
42.1 (CH2), 42.6 (CH2), 47.7 (CH), 49.7 (CH), 69.9 (C-3),
85.1 (C-17), 94.9 (C-16), 120.7 (C-6), 126.2 (2C, C-3′′ and
C-5′′), 128.7 (2C, C-2′′ and C-6′′), 129.6 (C-4′′), 129.9 (C-
1′′), 141.3 (C-5), 156.4 (C-3′); ESI-MS 445 [M+Na]+; Anal.




Substrate: 11b (195 mg). 12b was obtained as a white solid
(186 mg, 95 %), mp 227–230 ◦C, Rf = 0.44 (ss C); 1H NMR
(DMSO-d6, 500 MHz): δH 0.66 (s, 3H, 18-H3), 0.95 (s, 3H,
19-H3), 0.99 (m, 2H), 1.17 (m, 2H), 1.32–1.40 (overlapping
m, 3H), 1.47–1.55 (overlapping m, 3H), 1.67 (m, 1H), 1.76
(m, 2H), 1.89 (m, 1H), 1.98 (m, 1H), 2.07-2.16 (overlapping
m, 2H), 2.33 (s, 3H, 4′′-CH3), 2.96 (d, 1H, J = 17.1 Hz, one
of 4′-H), 3.27 (m, 1H, 3-H), 3.61 (d, 1H, J = 4.8 Hz, 17-H),
3.74 (d, 1H, J = 17.1 Hz, the other 4′-H), 4.60 (d, 1H, J = 4.4
Hz, 3-OH), 5.26 (m, 1H, 6-H), 5.30 (d, 1H, J = 4.9 Hz, 17-
OH), 7.23 (d, 2H, J = 7.8 Hz, 3′′-H and 5′′-H), 7.55 (d, 2H, J
= 7.8 Hz, 2′′-H and 6′′-H); 13C NMR (DMSO-d6, 125 MHz):
δC 11.4 (C-18), 19.1 (C-19), 19.9 (CH2), 20.9 (4′′-CH3), 30.7
(CH), 30.9 (CH2), 31.3 (CH2), 36.1 (CH2), 36.3 (C-10), 36.7
(CH2), 41.2 (CH2), 41.6 (C-13), 42.1 (CH2), 42.6 (CH2),
47.7 (CH), 49.6 (CH), 69.9 (C-3), 85.0 (C-17), 94.6 (C-16),
120.1 (C-6), 126.2 (2C, C-2′′ and C-6′′), 127.1 (C-1′′), 129.2
(2C, C-3′′ and C-5′′), 139.2 (C-4′′), 141.2 (C-5), 156.2 (C-
3′); ESI-MS 437 [M+H]+; Anal. Calcd. for C28H37NO3 C
77.20; H 8.56. Found C 77.34; H 8.74.
Synthesis of 3β-hydroxy-3′-4′′-methoxyphenyl-spiro
[androst-5-ene-16,5′S-2′-isoxazolin]-17β-ol (12c)
Substrate: 11c (202 mg). 12c was obtained as a white solid
(197 mg, 97 %), mp 235–237 ◦C, Rf = 0.44 (ss C); 1H NMR
(DMSO-d6, 500 MHz): δH 0.66 (s, 3H, 18-H3), 0.95 (s, 3H,
19-H3), 0.97 (m, 1H), 1.14–1.27 (overlapping m, 3H), 1.31–
1.43 (overlapping m, 3H), 1.45–1.55 (overlapping m, 3H),
1.67–1.78 (m, 3H), 1.88 (m, 1H), 1.97 (m, 1H), 2.06–2.16
(overlapping m, 2H), 2.96 (d, 1H, J = 17.1 Hz, one of 4′-H),
3.26 (m, 1H, 3-H), 3.61 (d, 1H, J = 4.9 Hz, 17-H), 3.72 (d,
1H, J = 17.1 Hz, the other 4′-H), 3.78 (s, 3H, 4′′-OMe), 4.64
(d, 1H, J = 4.2 Hz, 3-OH), 5.26 (m, 1H, 6-H), 5.31 (d, 1H, J
= 4.9 Hz, 17-OH), 6.98 (d, 2H, J = 8.6 Hz, 3′′-H and 5′′-H),
7.59 (d, 2H, J = 8.6 Hz, 2′′-H and 6′′-H); 13C NMR (DMSO-
d6, 125 MHz): δC 11.4 (C-18), 19.1 (C-19), 20.0 (CH2), 30.8
(CH), 30.9 (CH2), 31.4 (CH2), 36.2 (CH2), 36.4 (C-10), 36.8
(CH2), 41.5 (CH2), 41.7 (C-13), 42.2 (CH2), 42.6 (CH2),
47.7 (CH), 49.7 (CH), 55.2 (4′′-OMe), 69.9 (C-3), 85.0 (C-
17), 94.5 (C-16), 114.1 (2C, C-3′′ and C-5′′), 120.1 (C-6),
122.4 (C-1′′), 127.8 (2C, C-2′′ and C-6′′), 141.3 (C-5), 156.0
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(C-3′), 160.3 (C-4′′); ESI-MS 475 [M+Na]+; Anal. Calcd.
for C28H37NO4 C 74.47; H 8.26. Found C 74.61; H 8.36.
Synthesis of 3β-hydroxy-3′-4′′-chlorophenyl-
spiro[androst-5-ene-16,5′S-2′-isoxazolin]-17β-ol (12d)
Substrate: 11d (204 mg). 12d was obtained as a white solid
(195 mg, 95 %), decomposed above 190◦C, Rf = 0.48 (ss
C); 1H NMR (DMSO-d6, 500 MHz): δH 0.66 (s, 3H, 18-H3),
0.95 (s, 3H, 19-H3), 1.00 (m, 2H), 1.19 (m, 2H), 1.31–1.43
(overlapping m, 3H), 1.49–1.55 (overlapping m, 3H), 1.68
(m, 1H), 1.76 (m, 2H), 1.88 (m, 1H), 1.99 (m, 1H), 2.06–
2.17 (overlapping m, 2H), 3.01 (d, 1H, J = 17.2 Hz, one of
4′-H), 3.26 (m, 1H, 3-H), 3.62 (d, 1H, J = 4.9 Hz, 17-H),
3.76 (d, 1H, J = 17.2 Hz, the other 4′-H), 4.60 (d, 1H, J
= 4.4 Hz, 3-OH), 5.25 (m, 1H, 6-H), 5.33 (d, 1H, J = 5.0
Hz, 17-OH), 7.49 (d, 2H, J = 8.4 Hz, 3′′-H and 5′′-H), 7.68
(d, 2H, J = 8.4 Hz, 2′′-H and 6′′-H); 13C NMR (DMSO-
d6, 125 MHz): δC11.3 (C-18), 19.1 (C-19), 19.9 (CH2), 30.7
(CH), 30.9 (CH2), 31.3 (CH2), 36.1 (CH2), 36.3 (C-10), 36.7
(CH2), 40.9 (CH2), 41.5 (C-13), 42.1 (CH2), 42.6 (CH2),
47.6 (CH), 49.6 (CH), 69.8 (C-3), 85.0 (C-17), 95.3 (C-16),
120.0 (C-6), 127.7 (C-1′′), 127.9 (2C, C-3′′ and C-5′′), 128.7
(2C, C-2′′ and C-6′′), 134.1 (C-4′′), 141.3 (C-5), 155.6 (C-
3′); ESI-MS 479 [M+Na]+; Anal. Calcd. for C27H34ClNO3
C 71.11; H 7.52. Found C 71.01; H 7.64.
Synthesis of 3β-hydroxy-3′-4′′-nitrophenyl-
spiro[androst-5-ene-16,5′S-2′-isoxazolin]-17β-ol (12e)
Substrate: 11e (209 mg). 12e was obtained as a pale-yellow
solid (204 mg, 97 %), mp 271–274 ◦C, Rf = 0.49 (ss C);
1H NMR (DMSO-d6, 500 MHz): δH 0.67 (s, 3H, 18-H3),
0.95 (s, 3H, 19-H3), 0.99 (m, 2H), 1.20 (m, 2H), 1.31–1.43
(overlapping m, 3H), 1.50–1.58 (overlapping m, 3H), 1.68
(m, 1H), 1.76 (m, 2H), 1.88 (m, 1H), 2.01-2.17 (overlapping
m, 3H), 3.11 (d, 1H, J = 17.3 Hz, one of 4′-H), 3.27 (m, 1H,
3-H), 3.64 (d, 1H, J = 4.8 Hz, 17-H), 3.82 (d, 1H, J = 17.3 Hz,
the other 4′-H), 4.60 (d, 1H, J = 4.5 Hz, 3-OH), 5.26 (m, 1H,
6-H), 5.38 (d, 1H, J = 4.8 Hz, 17-OH), 7.92 (d, 2H, J = 8.7
Hz, 2′′-H and 6′′-H), 8.27 (d, 2H, J = 8.6 Hz, 3′′-H and 5′′-H);
13C NMR (DMSO-d6, 125 MHz): δC 11.3 (C-18), 19.1 (C-
19), 19.9 (CH2), 30.7 (CH), 30.8 (CH2), 31.3 (CH2), 36.1
(CH2), 36.2 (C-10), 36.7 (CH2), 40.5 (CH2), 41.5 (C-13),
42.1 (CH2), 42.6 (CH2), 47.6 (CH), 49.6 (CH), 69.8 (C-3),
85.0 (C-17), 96.4 (C-16), 120.0 (C-6), 123.9 (2C, C-3′′ and
C-5′′), 127.3 (2C, C-2′′ and C-6′′), 136.0 (C-1′′), 141.3 (C-
5), 147.6 (C-4′′), 155.4 (C-3′); ESI-MS 490 [M+Na]+; Anal.
Calcd. for C27H34N2O5 C 69.50; H 7.35. Found C 69.64; H
7.54.
Determination of antiproliferative activities
Antiproliferative effects were measured in vitro on three
human cancer cell lines (ECACC; Salisbury, UK): HeLa
(cervix adenocarcinoma), MCF7 (breast adenocarcinoma),
and A431 (skin epidermoid carcinoma). The cells were
cultivated in minimal essential medium (Sigma-Aldrich,
Budapest, Hungary) supplemented with 10 % fetal bovine
serum, 1 % non-essential amino acids, and an antibiotic-
antimycotic mixture. Near-confluent cells were seeded into a
96-well plate (5,000 cells/well) and, after overnight standing,
the medium (200 μL) containing the tested compound (at 10
or 30 μM) was added. Following a 72-h incubation period
in a humidified atmosphere of 5 % CO2 at 37 ◦C, the living
cells were assayed by the addition of 20 μL of 5 mg/mL
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] solution [44]. During a 4-h contact period, the MTT
was converted by intact mitochondrial reductase and precip-
itated as blue crystals. The medium was then removed, the
precipitated formazan crystals were solubilized in DMSO
(100 μL) during a 60-min period of shaking at 25 ◦C, and
the absorbance was read at 545 nm with a microplate reader.
Wells with untreated cells were utilized as controls. All in
vitro experiments were carried out on two microplates with
at least five parallel wells. Stock solutions of the tested sub-
stances (10 mM) were prepared with DMSO. The DMSO
concentration (0.3 %) of the medium did not have any signifi-
cant effect on cell proliferation. Cisplatin was used as a refer-
ence compound. A set of dilutions were additionally applied
in order to determine the IC50values of the most active com-
pounds. Sigmoidal dose–response curves were fitted to the
measured points, and the values were calculated by means of
GraphPad Prism 4.0 (GraphPad Software; San Diego, CA,
USA).
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